Eli Lilly and Company (LLY.SW)
| Previous close | 690.00 |
| Open | 690.00 |
| Bid | 655.00 x 0 |
| Ask | 785.00 x 0 |
| Day's range | 690.00 - 690.00 |
| 52-week range | 384.00 - 740.00 |
| Volume | |
| Avg. volume | 1,692 |
| Market cap | 655.779B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 111.11 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 4.56 (0.66%) |
| Ex-dividend date | 14 Feb 2024 |
| 1y target est | N/A |
- PR Newswire
Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum
Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first quarter of 2024.
- PR Newswire
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
Eli Lilly and Company (NYSE: LLY) today announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints. Percentage change in AHI was a key secondary endpoint in both studies. AHI records the number of times a person's breathing shows a restricted or complete block of airflow per hour of sleep and is used to evaluate the sever
- PR Newswire
Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement
Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2024 financial results on April 30, 2024. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.
